Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Nplate Review Shows Struggle For Early Implementation Of REMS

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Review deadline for Amgen’s romiplostim came only one month after REMS authority went into effect. Back and forth on risk management program shows agency desire for specific examples. Amgen cites need for guidance from FDA

You may also be interested in...

Fast Track Speeds Approval, Tufts Finds; Therapeutic Category Also Key

FDA’s fast track program may be the most successful of FDA’s user fee-era regulatory initiatives aimed at speeding new drug reviews, an analysis by the Tufts Center for the Study of Drug Development suggests.

Living With REMS: The New Regulatory Model Meets Commercial Reality

Amgen and GSK are competing head-to-head in a new market for a rare blood disorder. The market size is small, but the commercial implications are huge: how will the new regulatory tools imposed by FDA affect competition in the real world?

The New User Fee Rules: FDA Sacrifices Timeliness, Tries to Save Predictability

Janet Woodcock is returning as director of CDER at a time when the user fee program is in flux and FDA is struggling to implement new drug safety initiatives. For 2008, timeliness of reviews will slip, but with any luck, the transparency and predictability of PDUFA will continue.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts